Core Viewpoint - Investors suffering losses from Kyverna Therapeutics, Inc. are encouraged to participate in a class action lawsuit due to alleged securities fraud related to undisclosed adverse data from clinical trials [4][5]. Group 1: Class Action Details - The class period for the lawsuit begins from the February 2024 IPO [3]. - The deadline for lead plaintiffs to come forward is set for February 7, 2025 [3]. - Investors do not need to take any immediate action to be part of the class action; they can choose to retain counsel or remain absent [3]. Group 2: Allegations Against Kyverna - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials [5]. - It is claimed that the company withheld this adverse data, which misled investors regarding the company's business and operational prospects [5]. - The positive statements made by the company about its operations were allegedly materially misleading and lacked a reasonable basis [5].

LOS ANGELES, Dec. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to co ...

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=117784&from=4 CLASS PERIOD: ...

Core Viewpoint - A class action lawsuit has been filed against Kyverna Therapeutics, Inc. for alleged securities fraud and unlawful business practices [1][3]. Group 1: Class Action Details - The class action lawsuit is initiated by Pomerantz LLP, and shareholders who acquired DMC securities during the Class Period can request to be appointed as Lead Plaintiff by February 7, 2025 [2][3]. - A copy of the Complaint is available at Pomerantz's website [2]. Group 2: Company Background and IPO - Kyverna Therapeutics conducted its initial public offering (IPO) on February 8, 2024, offering 14.5 million shares at a price of $22.00 per share [4]. - On the same day, the company disclosed adverse data from a clinical trial, leading to a significant drop in stock price [5]. Group 3: Stock Performance - Following the adverse disclosures, Kyverna's stock price fell by $4.91, or 34%, closing at $9.53 per share on June 14, 2024 [5].

Core Viewpoint - The article discusses a federal securities class action lawsuit against Kyverna Therapeutics, Inc. due to alleged violations of federal securities laws related to its initial public offering (IPO) [4][6]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Kyverna and has set a deadline of February 7, 2025, for investors to seek the role of lead plaintiff in the class action [4]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [1]. Group 2: Allegations Against Kyverna - The complaint alleges that Kyverna and its executives misrepresented and omitted critical information regarding the results of clinical trials for KYV-101 in the registration statement and prospectus used during the IPO [6]. - Specifically, the company claimed patient "improvement" in certain indicators while failing to disclose adverse data known at the time of the IPO [6]. Group 3: Financial Impact - Following the emergence of the true facts post-IPO, Kyverna's shares experienced a significant decline, trading as low as $3.92 per share, which represents a drop of over 82% from the offering price [7]. - Investors who suffered losses exceeding $50,000 are encouraged to contact the law firm to discuss their legal options [3].

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...

SAN DIEGO, Dec. 19, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna's registration statement issued in connection with Kyverna's initial public offering (the "IPO") held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-088 ...

RADNOR, Pa., Dec. 19, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=117290&from=4CLASS PERIOD: T ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faru ...